Abstracts tagged "Autoinflammatory diseases"

Abstract Number: 0013 • ACR Convergence 2025
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Xiaofeng Zhao¹, Xiaoqing Liu¹, Yuxi Yan², Tiezheng Liu³, Yong Fu³, Yulan Hu², Kangmin Zhou², Minyun Zhou⁴, Yingying Hu² and Shunwei Zhu², ¹State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing
Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
Abstract Number: 2134 • ACR Convergence 2025
Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Eileen Rife¹, Lexi Auld², Guihua Zhai³, Esraa Eloseily⁴, Grant Schulert⁵ and Yukiko Kimura⁶, ¹University of Alabama at Birmingham, birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³UAB, Birmingham, ⁴UT Southwestern Children's Medical Center, Dallas, TX, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Children with Systemic Juvenile Idiopathic Arthritis (SJIA) who develop lung disease (LD) are at significantly increased risk of serious complications and even death. Early…
Abstract Number: 1713 • ACR Convergence 2025
Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients
Mohamed Abdelsalam¹, Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Abdelhfeez Moshrif⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Al Azhar University, Asyut, Egypt, assyut, Asyut, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Psoriatic arthritis (PsA) remains widely underdiagnosed and misdiagnosed worldwide, leading to delays in appropriate management and increased disease burden. While diagnostic delay has been…
Abstract Number: 1171 • ACR Convergence 2025
VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy
Marta López¹, Paula Garcia Escudero², Berta Magallares³, Meritxell Salles Lizarzaburu⁴, Dolly Viviana Fiallo Suárez⁵, Iñigo Rúa-Figueroa⁶, Isla Morante Bolado⁷, Elena Aurrecoechea⁸, Eugenia Enriquez⁹, Carolina Merino¹⁰, Santos Castañeda¹¹, Irene Monjo Henry¹², César Antonio Egües Dubuc¹³, Elena María Oliver García¹⁴, Alicia Garcia¹⁵, Judit Font-Urgelles¹⁶, Cristina Corrales¹⁷, Lourdes Villalobos¹⁸, Alina-Lucica Boteanu¹⁹, Ignacio Vázquez Gómez²⁰, Diego Dios²¹, Clara Garcia Belando²², Beatriz Frade Sosa²³, Delia Reina²⁴, Marta Ibañez²⁵, Irene Carrion²⁶, Maria Rodriguez²⁷, cristiana Sieiro²⁸, Francisco Javier Toyos²⁹, Alberto Mariano³⁰, Clara Moriano³¹, Rafael B. Melero-González³², Paloma Vela Casasempere³³, Jose Alberto Miranda³⁴, Giuliano Boselli³⁵, Jose Angel Hernandez³⁶, Ernesto Trallero³⁷, Elena Riera Alonso³⁸ and Jaime Calvo³⁹, ¹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ²H.U.Araba, Vitoria, ³Hospital de Sant Pau, Bareclona, ⁴Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ⁵H.U. Doctor Negrín, Gran Canarias, ⁶Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁷Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁸H. Sierrallana, Santander, ⁹Clínica Universidad de Navarra, Madrid, Spain, ¹⁰Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ¹⁴H.C. U. Lozano Blesa, Zaragoza, ¹⁵Rheumatologist, La Laguna, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, ¹⁸Ramon y Cajal Hospital, MADRID, Spain, ¹⁹H.U. Ramón y Cajal, Madrid, Spain, ²⁰H.U. Doctor Peset, Valencia, ²¹H.U de A Coruña, A Coruña, Spain, ²²H.C. U. Virgen de la arrizaca, Murcia, ²³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ²⁶Hospital del Mar, Barcelona, Spain, ²⁷H. Clínico San Carlos, Madrid, Spain, ²⁸Univrsity of Manchester, Manchester, United Kingdom, ²⁹Virgen Macarena University Hospital,, Sevilla, Spain, ³⁰Virgen del Rocío University Hospital, Sevilla, Spain, ³¹Hospital León, LEON, Castilla y Leon, Spain, ³²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ³³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ³⁴C. H. U. Lucus Augusti, Lugo, Spain, ³⁵Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ³⁶Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, ³⁷H. U. Vall d'Hebron, Barcelona, ³⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ³⁹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in UBA1 gene, characterized by systemic inflammation and haematologic abnormalities. Evidence regarding its…
Abstract Number: 0779 • ACR Convergence 2025
Interim Results of a Randomized Placebo Controlled Study of IL-1 Inhibitor Goflikicept in Patients With Familial Mediterranean Fever
Olga Uhanova¹, serdal Ugurlu², Mikhail Kostik³, Tamara Sarkisyan⁴, Anna Yeghiazaryan⁴, Lidiya Lysenko⁵, Vilen Rameev⁵, Omer Karadag⁶, Valentina Vardanyan⁷, Veli Yazisiz⁸, Tatiana Sotnikova⁹, Vyacheslav Podsvirov¹, Alina Egorova¹⁰, Daria Bukhanova¹⁰, Sergey Grishin¹⁰, Tolga Tuncel¹¹, Mikhail Samsonov¹⁰ and Ahmet Gul¹², ¹Terafarm LLC, Stavropol, Russia, ²Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁴Center of Medical Genetics and Primary Health Care LTD, Yerevan, Armenia, ⁵Sechenov’s ¹st State Moscow Medical University, Moscow, Russia, ⁶Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, ⁷Ecosense Diagnostic Center, Yerevan, Armenia, ⁸Akdeniz University, Faculty of Medicine, Antalya, Turkey, ⁹State Budgetary Institution of Healthcare of Moscow Multispeciality Hospital named after S.P. Botkin of the Moscow City and Sechenov University, Moscow, Russia, ¹⁰R-Pharm JSC, Moscow, Russia, ¹¹TRpharm, Istanbul, Turkey, ¹²Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Goflikicept (GFC; RPH-104) is a novel fusion protein inhibiting interleukin-1 (IL-1). This study aimed to investigate its efficacy and safety in IL-1β-driven monogenic autoinflammatory…
Abstract Number: 0586 • ACR Convergence 2025
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
Abstract Number: 2129 • ACR Convergence 2025
Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses
Marci Macaraeg¹, Nadine Saad², Tiphanie Vogel³, Fatma Dedeoglu⁴, Kyle McBrearty⁴, Qin Sun⁵, Chunyan Liu⁵ and Grant Schulert⁵, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Michigan, Ann Arbor, MI, ³Baylor College of Medicine, Houston, TX, ⁴Boston Children's Hospital, Boston, MA, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Syndrome of Undifferentiated Recurrent Fevers (SURF) refers to patients with recurrent fevers who do not meet clinical or classification criteria for Periodic Fevers, Aphthous…
Abstract Number: 1669 • ACR Convergence 2025
Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
Farzana Nuruzzaman¹, Natalie Rossenwasser², Xing Wang³, Ava Klein³, Ian Muse⁴, Erin Balay-Dustrude⁵, Megan Nguyen⁶, Emily Deng³, Jonathan Akikusa⁷, Matthew Basiaga⁸, Lindsey Bergstrom⁹, Fatma Dedeoglu¹⁰, Bin Huang¹¹, Jenna King¹², Sivia Lapidus¹³, Tzielan Lee¹⁴, Aleksander Lenert¹⁵, Cassandra Levesque¹⁶, Lillian Lim¹⁷, Kimberly Martin¹⁸, Elizabeth Murray¹⁹, Melissa Oliver²⁰, Karen Onel²¹, Seza Özen²², Lauren Potts²³, Sara M. Stern²⁴, Robin Villaverda²⁵, Eveline Wu²⁶, Ronald laxer²⁷, Polly Ferguson²⁸, Daniel Lovell²⁹ and Yongdong (Dan) Zhao³⁰, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Seattle Children's Hospital, Seattle, WA, ³Seattle Children's Hospital, Seattle, ⁴University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, Seattle, ⁷The Royal Children's Hospital, Parkville, Victoria, Australia, ⁸Mayo Clinic, Rochester, MN, ⁹Patient/parent research partner, Harpswell, ME, ¹⁰Boston Children's Hospital, Boston, MA, ¹¹Cincinnati Children's Hospital, Cinciannati, OH, ¹²Patient/parent Research Partner, Planation, FL, ¹³Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Iowa Carver College of Medicine, Iowa City, IA, ¹⁶Patient/parent research partners, DC district, DC, ¹⁷University of Alberta, Edmonton, AB, Canada, ¹⁸Patient/parent research partners, Houston, TX, ¹⁹Patient/parent research partners, Lynnwood, WA, ²⁰Indiana University, Indianapolis, IN, ²¹HSS, New York, NY, ²²Hacettepe University Medical Faculty, Ankara, Turkey, ²³Patient/parent research partners, Santa Cruiz, CA, ²⁴University of Utah, Salt Lake City, UT, ²⁵Patient/parent research partners, Thorton, CO, ²⁶UNC Chapel Hill, Chapel Hill, NC, ²⁷The Hospital for Sick Children, Toronto, ON, Canada, ²⁸University of Iowa Carver College of Medicine, Iowa City, IA, ²⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁰Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an inflammatory bone disease that can result in bone destruction/deformity, persistent bone pain and pathological fractures. Due to the…
Abstract Number: 1170 • ACR Convergence 2025
A20 Haploinsufficiency (HA20): TNFAIP3 Mutation Prevalence In A Clinically Compatible Cohort
María Alonso de Francisco¹, Emiliano González Vioque², Pablo Navarro Palomo³, Maria Machattou⁴, Carlota Navarro Joven⁴, Laura Ramos Ortiz de Zarate⁴, Alejandro Martínez⁵, Adriana Martín Bescós⁴, Paula Mazo⁴, María Concepción Sánchez Fernández⁴, Andrea Liso Andrino⁴, Maria Carmen Barbadillo Mateos⁶, JESUS SANZ SANZ⁷, Hildegarda Godoy Tundidor⁴, Jose Campos⁸, Monica Fernandez Castro⁹, Blanca García Magallón⁴, Olga Rusinovich¹⁰, Laura Nuño¹¹, Jose Luis Andreu¹² and Carolina Merino¹³, ¹H. U. Puerta de Hierro Majadahonda, Tres Cantos, Spain, ²Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Afghanistan, ⁶Public, Madrid, Spain, ⁷SERMAS, Madrid, Spain, ⁸Hospital Universitario Principe de Asturias, Madrid, Spain, ⁹PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ¹⁰Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ¹¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹³Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain
Background/Purpose: Haploinsufficiency of A20 (HA20) is a disease at the crossroads between autoinflammation and autoimmunity, caused by heterozygous mutations in TNFAIP3, which encodes the A20…
Abstract Number: 0778 • ACR Convergence 2025
Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome
Erdem Bektas¹, Burcu Ceren Uludogan², Büşra Fırlatan Yazgan³, Ozgur Can Kilinc⁴, Beste Acar⁴, Oguzhan Omer Kizilkaya⁴, Aysenur Yilmaz⁵, Busra Yuce⁶, serdal Ugurlu⁷, Umut Kalyoncu³, Timucin Kasifoglu² and Cemal Bes⁸, ¹Istanbul University, Institute of Graduate Studies in Health Sciences, Immunology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁴Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Department of Rheumatology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, ⁶Department of Internal Medicine, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, ⁷Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Still's disease (SD) is a autoinflammatory disease (AID) characterized by a wide range of clinical manifestations and can exhibit life-threatening macrophage activation syndrome (MAS).…
Abstract Number: 2667 • ACR Convergence 2025
Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models
Berkay Aktas¹, Enes Azman¹, Yusuf Ecren Oner², kadir Kaya², husnu Mert Yuksel³, Ali Hosgel², Dilan Karahan², Zehra Beyza Coban², Kerem parlar⁴, Ozgur Can Kilinc¹, Beste Acar¹ and serdal Ugurlu⁵, ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ⁴Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by MEFV mutations. Amyloidosis remains its most serious complication, with several risk factors reported…
Abstract Number: 2125 • ACR Convergence 2025
Development and Validation of Minimal Clinically Important Difference for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
Farzana Nuruzzaman¹, Natalie Rosenwasser², Xing Wang³, Ava Klein³, Ian Muse⁴, Erin Balay-Dustrude⁵, Megan Nguyen⁶, Emily Deng³, Jonathan Akikusa⁷, Matthew Basiaga⁸, Lindsey Bergstrom⁹, Fatma Dedeoglu¹⁰, Bin Huang¹¹, Jenna King¹², Sivia Lapidus¹³, Tzielan Lee¹⁴, Cassandra Levesque¹⁵, Aleksander Lenert¹⁶, Lillian Lim¹⁷, Kimberly Martin¹⁸, Elizabeth Murray¹⁹, Melissa Oliver²⁰, Karen Onel²¹, Seza Özen²², Lauren Potts²³, Sara M. Stern²⁴, Robin Villaverda²⁵, Eveline Wu²⁶, Ronald laxer²⁷, Polly Ferguson²⁸, Daniel Lovell²⁹ and Yongdong (Dan) Zhao³⁰, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Seattle Children's Hospital, seattle, WA, ³Seattle Children's Hospital, Seattle, ⁴University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, Seattle, ⁷The Royal Children's Hospital, Parkville, Victoria, Australia, ⁸Mayo Clinic, Rochester, MN, ⁹Patient/parent research partner, Harpswell, ME, ¹⁰Boston Children's Hospital, Boston, MA, ¹¹Cincinnati Children's Hospital, Cinciannati, OH, ¹²Patient/parent Research Partner, Planation, FL, ¹³Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Patient/parent research partners, DC district, DC, ¹⁶Iowa Carver College of Medicine, Iowa City, IA, ¹⁷University of Alberta, Edmonton, AB, Canada, ¹⁸Patient/parent research partners, Houston, TX, ¹⁹Patient/parent research partners, Lynnwood, WA, ²⁰Indiana University, Indianapolis, IN, ²¹HSS, New York, NY, ²²Hacettepe University Medical Faculty, Ankara, Turkey, ²³Patient/parent research partners, Santa Cruiz, CA, ²⁴University of Utah, Salt Lake City, UT, ²⁵Patient/parent research partners, Thorton, CO, ²⁶UNC Chapel Hill, Chapel Hill, NC, ²⁷The Hospital for Sick Children, Toronto, ON, Canada, ²⁸University of Iowa Carver College of Medicine, Iowa City, IA, ²⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁰Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an inflammatory bone disease that can result in bone deformity, persistent pain and pathological fractures which is frequently treated…
Abstract Number: 1670 • ACR Convergence 2025
Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features
Shima Yasin¹, Shima Yasin² and Polly Ferguson³, ¹King Abdullah Specialized Children’s Hospital,Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia, ²Univeristy of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease that affects children and adolescents. The disease typically presents with bone pain with or…
Abstract Number: 1169 • ACR Convergence 2025
Periodontitis in neutropenic DADA2 patients
Lorena Wilson¹, Amanda Ombrello², Patrycja Hoffmann³, Cornelia Cudrici³, Tina Romeo⁴ and Daniel L. Kastner⁵, ¹National Institutes of Health, Silver Spring, ²National Institutes of Health, Rockville, MD, ³National Insitutes of Health, Bethesda, ⁴NIH, Bethesda, MD, ⁵National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by pathogenic mutations in ADA2. Severe and refractory neutropenia is a hematologic…
Abstract Number: 0494 • ACR Convergence 2025
LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
Matt McClure¹, Catherine Carriere¹, Kierstin Bell¹, Rex Williams², Geoff Kuesters², Emily Sansevere², Dave Nichols², Arthur Tzianabos² and Jay Rothstein¹, ¹Lifordi Immunotherapeutics, Lebanon, NH, ²Lifordi Immunotherapeutics, Burlington, MA
Background/Purpose: Glucocorticoids (GCs) are the most versatile and efficacious anti-inflammatory drugs rheumatologists have available for patients. Unfortunately, prolonged systemic GC exposure leads to unacceptable toxicities,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].